{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:38:46Z","timestamp":1792697926455,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,29]]},"DOI":"10.7759\/cureus.39624","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T05:03:58Z","timestamp":1685336638000},"source":"Crossref","is-referenced-by-count":34,"title":["Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness"],"prefix":"10.7759","author":[{"given":"Madhurima","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pansy Prardhana Sinha","family":"Bakka Vemana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muktha S","family":"Bellary Pattanashetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain U","family":"Abdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humza F","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng Y","year":"2022","unstructured":"Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022, 9:62-79. 10.1016\/j.gendis.2021.02.009","journal-title":"Genes Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/20.1.60","article-title":"Review: antioxidant protection of the ageing macula","volume":"20","author":"Gerster H","year":"1991","unstructured":"Gerster H. Review: antioxidant protection of the ageing macula. Age Ageing. 1991, 20:60-9. 10.1093\/ageing\/20.1.60","journal-title":"Age Ageing"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36048","article-title":"Prevalence and associated risk factors of age-related macular degeneration in the retina clinic at a tertiary center in Makkah Province, Saudi Arabia: a retrospective record review","volume":"15","author":"Abusharkh FH","year":"2023","unstructured":"Abusharkh FH, Kurdi L, Shigdar RW, Mandura RA, Alattas K. Prevalence and associated risk factors of age-related macular degeneration in the retina clinic at a tertiary center in Makkah Province, Saudi Arabia: a retrospective record review. Cureus. 2023, 15:e36048. 10.7759\/cureus.36048","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong WL","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014, 2:106-16. 10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2021.01.003","article-title":"Age-related macular degeneration","volume":"105","author":"Thomas CJ","year":"2021","unstructured":"Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021, 105:473-91. 10.1016\/j.mcna.2021.01.003","journal-title":"Med Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.10.003","article-title":"Association of age-related macular degeneration and reticular macular disease with cardiovascular disease","volume":"61","author":"Rastogi N","year":"2016","unstructured":"Rastogi N, Smith RT. Association of age-related macular degeneration and reticular macular disease with cardiovascular disease. Surv Ophthalmol. 2016, 61:422-33. 10.1016\/j.survophthal.2015.10.003","journal-title":"Surv Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.09.022","article-title":"Cigarette smoking and age-related macular degeneration in the EUREYE study","volume":"114","author":"Chakravarthy U","year":"2007","unstructured":"Chakravarthy U, Augood C, Bentham GC, et al.. Cigarette smoking and age-related macular degeneration in the EUREYE study. Ophthalmology. 2007, 114:1157-63. 10.1016\/j.ophtha.2006.09.022","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.02.025","article-title":"Risk factors for four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino eye study","volume":"152","author":"Choudhury F","year":"2011","unstructured":"Choudhury F, Varma R, McKean-Cowdin R, Klein R, Azen SP. Risk factors for four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino eye study. Am J Ophthalmol. 2011, 152:385-95. 10.1016\/j.ajo.2011.02.025","journal-title":"Am J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris FL 3rd","year":"1984","unstructured":"Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984, 102:1640-2. 10.1001\/archopht.1984.01040031330019","journal-title":"Arch Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2020.0513","article-title":"The diagnosis and treatment of age-related macular degeneration","volume":"117","author":"Stahl A","year":"2020","unstructured":"Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020, 117:513-20. 10.3238\/arztebl.2020.0513","journal-title":"Dtsch Arztebl Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"29","author":"Mitchell P","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018, 29:1147-59. 10.1016\/S0140-6736(18)31550-2","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.09.027","article-title":"Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis","volume":"119","author":"Rudnicka AR","year":"2012","unstructured":"Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012, 119:571-80. 10.1016\/j.ophtha.2011.09.027","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.10.007","article-title":"The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis","volume":"117","author":"Kawasaki R","year":"2010","unstructured":"Kawasaki R, Yasuda M, Song SJ, et al.. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010, 117:921-7. 10.1016\/j.ophtha.2009.10.007","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/07853890600946724","article-title":"Age-related macular degeneration - emerging pathogenetic and therapeutic concepts","volume":"38","author":"Gehrs KM","year":"2006","unstructured":"Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration - emerging pathogenetic and therapeutic concepts. Ann Med. 2006, 38:450-71. 10.1080\/07853890600946724","journal-title":"Ann Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein DB","year":"2022","unstructured":"Rein DB, Wittenborn JS, Burke-Conte Z, et al.. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022, 140:1202-8. 10.1001\/jamaophthalmol.2022.4401","journal-title":"JAMA Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon N","year":"2004","unstructured":"Congdon N, O'Colmain B, Klaver CC, et al.. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004, 122:477-85. 10.1001\/archopht.122.4.477","journal-title":"Arch Ophthalmol"},{"key":"ref17","unstructured":"World Health Organization. Blindness and Vision Impairment. (2022). Accessed. May 9, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment.."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.013","article-title":"Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis, and modelling","volume":"125","author":"Fricke TR","year":"2018","unstructured":"Fricke TR, Tahhan N, Resnikoff S, et al.. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis, and modelling. Ophthalmology. 2018, 125:1492-9. 10.1016\/j.ophtha.2018.04.013","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.22608\/APO.2017251","article-title":"Updates on the epidemiology of age-related macular degeneration","volume":"6","author":"Jonas JB","year":"2017","unstructured":"Jonas JB, Cheung CM, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila). 2017, 6:493-7. 10.22608\/APO.2017251","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010","volume":"153","author":"Bloch SB","year":"2012","unstructured":"Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012, 153:209-213.e2. 10.1016\/j.ajo.2011.10.016","journal-title":"Am J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.58","article-title":"Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments","volume":"127","author":"Rein DB","year":"2009","unstructured":"Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009, 127:533-40. 10.1001\/archophthalmol.2009.58","journal-title":"Arch Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(05)80070-5","article-title":"Age-related macular degeneration: economic burden and value-based medicine analysis","volume":"40","author":"Brown MM","year":"2005","unstructured":"Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol. 2005, 40:277-87. 10.1016\/S0008-4182(05)80070-5","journal-title":"Can J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7387.485","article-title":"Age related macular degeneration","volume":"326","author":"Chopdar A","year":"2003","unstructured":"Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ. 2003, 326:485-8. 10.1136\/bmj.326.7387.485","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(03)00030-4","article-title":"Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies","volume":"48","author":"Ambati J","year":"20031","unstructured":"Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Survey of ophthalmology. 20031, 48:257-93. 10.1016\/S0039-6257(03)00030-4","journal-title":"Survey of ophthalmology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2174\/1566524019666190828150625","article-title":"Molecular mechanisms of complement system proteins and matrix metalloproteinases in the pathogenesis of age-related macular degeneration","volume":"19","author":"Mansoor N","year":"2019","unstructured":"Mansoor N, Wahid F, Azam M, Shah K, den Hollander AI, Qamar R, Ayub H. Molecular mechanisms of complement system proteins and matrix metalloproteinases in the pathogenesis of age-related macular degeneration. Curr Mol Med. 2019, 19:705-18. 10.2174\/1566524019666190828150625","journal-title":"Curr Mol Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.1376","article-title":"Characterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomography","volume":"138","author":"Waldstein SM","year":"2020","unstructured":"Waldstein SM, Vogl WD, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth U. Characterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomography. JAMA Ophthalmol. 2020, 138:740-7. 10.1001\/jamaophthalmol.2020.1376","journal-title":"JAMA Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010329","article-title":"Abundant lipid and protein components of drusen","volume":"5","author":"Wang L","year":"2010","unstructured":"Wang L, Clark ME, Crossman DK, Kojima K, Messinger JD, Mobley JA, Curcio CA. Abundant lipid and protein components of drusen. PLoS One. 2010, 5:e10329. 10.1371\/journal.pone.0010329","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12675","article-title":"Risk factors for progression of age-related macular degeneration","volume":"40","author":"Heesterbeek TJ","year":"2020","unstructured":"Heesterbeek TJ, Lor\u00e9s-Motta L, Hoyng CB, Lechanteur YT, den Hollander AI. Risk factors for progression of age-related macular degeneration. Ophthalmic Physiol Opt. 2020, 40:140-70. 10.1111\/opo.12675","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.5.17","article-title":"Genetic susceptibility, diet quality, and two-step progression in drusen size","volume":"61","author":"Merle BM","year":"2020","unstructured":"Merle BM, Rosner B, Seddon JM. Genetic susceptibility, diet quality, and two-step progression in drusen size. Invest Ophthalmol Vis Sci. 2020, 61:17. 10.1167\/iovs.61.5.17","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref30","article-title":"Lipofuscin and age-related macular degeneration","author":"Luo MM","year":"2019","unstructured":"Luo MM. Lipofuscin and age-related macular degeneration. Int Eye Sci. 2019, 1326-9.","journal-title":"Int Eye Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200206000-00007","article-title":"Risk factors for age-related macular degeneration: an update","volume":"13","author":"Hyman L","year":"2002","unstructured":"Hyman L, Neborsky R. Risk factors for age-related macular degeneration: an update. Curr Opin Ophthalmol. 2002, 13:171-5. 10.1097\/00055735-200206000-00007","journal-title":"Curr Opin Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6257(00)00140-5","article-title":"The role of oxidative stress in the pathogenesis of age-related macular degeneration","volume":"45","author":"Beatty S","year":"2000","unstructured":"Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000, 45:115-34. 10.1016\/s0039-6257(00)00140-5","journal-title":"Surv Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1718059115","article-title":"CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation","volume":"115","author":"Vavvas DG","year":"2018","unstructured":"Vavvas DG, Small KW, Awh CC, Zanke BW, Tibshirani RJ, Kustra R. CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. Proc Natl Acad Sci U S A. 2018, 115:E696-704. 10.1073\/pnas.1718059115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S298310","article-title":"Associations of ARMS2 and CFH gene polymorphisms with neovascular age-related macular degeneration","volume":"15","author":"Supanji S","year":"2021","unstructured":"Supanji S, Romdhoniyyah DF, Sasongko MB, et al.. Associations of ARMS2 and CFH gene polymorphisms with neovascular age-related macular degeneration. Clin Ophthalmol. 2021, 15:1101-8. 10.2147\/OPTH.S298310","journal-title":"Clin Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"5","author":"Lim LS","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012, 5:1728-38. 10.1016\/S0140-6736(12)60282-7","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-10-31","article-title":"Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Chakravarthy U","year":"2010","unstructured":"Chakravarthy U, Wong TY, Fletcher A, et al.. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010, 10:31. 10.1186\/1471-2415-10-31","journal-title":"BMC Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-090413-025610","article-title":"Age-related macular degeneration: genetics and biology coming together","volume":"15","author":"Fritsche LG","year":"2014","unstructured":"Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014, 15:151-71. 10.1146\/annurev-genom-090413-025610","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein RJ","year":"2005","unstructured":"Klein RJ, Zeiss C, Chew EY, et al.. Complement factor H polymorphism in age-related macular degeneration. Science. 2005, 308:385-9. 10.1126\/science.1109557","journal-title":"Science"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1143","article-title":"Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers","volume":"47","author":"Sepp T","year":"2006","unstructured":"Sepp T, Khan JC, Thurlby DA, et al.. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006, 47:536-40. 10.1167\/iovs.05-1143","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.182568","article-title":"Determination of a gene and environment risk model for age-related macular degeneration","volume":"94","author":"Gibson J","year":"2010","unstructured":"Gibson J, Cree A, Collins A, Lotery A, Ennis S. Determination of a gene and environment risk model for age-related macular degeneration. Br J Ophthalmol. 2010, 94:1382-7. 10.1136\/bjo.2010.182568","journal-title":"Br J Ophthalmol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(00)00961-2","article-title":"Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation","volume":"131","author":"Anderson DH","year":"2001","unstructured":"Anderson DH, Ozaki S, Nealon M, Neitz J, Mullins RF, Hageman GS, Johnson LV. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol. 2001, 131:767-81. 10.1016\/s0002-9394(00)00961-2","journal-title":"Am J Ophthalmol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.12.012","article-title":"Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study","volume":"186","author":"Eiriksdottir G","year":"2006","unstructured":"Eiriksdottir G, Aspelund T, Bjarnadottir K, Olafsdottir E, Gudnason V, Launer LJ, Harris TB. Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study. Atherosclerosis. 2006, 186:222-4. 10.1016\/j.atherosclerosis.2005.12.012","journal-title":"Atherosclerosis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1446","article-title":"Apolipoprotein localization in isolated drusen and retinal apolipoprotein gene expression","volume":"47","author":"Li CM","year":"2006","unstructured":"Li CM, Clark ME, Chimento MF, Curcio CA. Apolipoprotein localization in isolated drusen and retinal apolipoprotein gene expression. Invest Ophthalmol Vis Sci. 2006, 47:3119-28. 10.1167\/iovs.05-1446","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(00)00643-7","article-title":"The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration","volume":"130","author":"Friedman E","year":"2000","unstructured":"Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000, 130:658-63. 10.1016\/s0002-9394(00)00643-7","journal-title":"Am J Ophthalmol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2003.11.026","article-title":"Pathogenesis of lesions in late age-related macular disease","volume":"137","author":"Holz FG","year":"2004","unstructured":"Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol. 2004, 137:504-10. 10.1016\/j.ajo.2003.11.026","journal-title":"Am J Ophthalmol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302281","article-title":"Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis","volume":"97","author":"Sui GY","year":"2013","unstructured":"Sui GY, Liu GC, Liu GY, et al.. Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis. Br J Ophthalmol. 2013, 97:389-94. 10.1136\/bjophthalmol-2012-302281","journal-title":"Br J Ophthalmol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249752","article-title":"Associations between the complement system and choroidal neovascularization in wet age-related macular degeneration","volume":"21","author":"Jensen EG","year":"2020","unstructured":"Jensen EG, Jakobsen TS, Thiel S, Askou AL, Corydon TJ. Associations between the complement system and choroidal neovascularization in wet age-related macular degeneration. Int J Mol Sci. 2020, 21:10.3390\/ijms21249752","journal-title":"Int J Mol Sci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34920","article-title":"Age-related macular degeneration and its association with neurodegenerative disorders","volume":"15","author":"Mody S","year":"2023","unstructured":"Mody S, Joshi A. Age-related macular degeneration and its association with neurodegenerative disorders. Cureus. 2023, 15:e34920. 10.7759\/cureus.34920","journal-title":"Cureus"},{"key":"ref49","article-title":"Age-related macular degeneration","volume":"59","author":"Gheorghe A","year":"2015","unstructured":"Gheorghe A, Mahdi L, Musat O. Age-related macular degeneration. Rom J Ophthalmol. 2015, 59:74-7.","journal-title":"Rom J Ophthalmol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216274","article-title":"Early stages of age-related macular degeneration: racial\/ethnic differences and proposal of a new classification incorporating emerging concept of choroidal pathology","volume":"11","author":"Sasaki M","year":"2022","unstructured":"Sasaki M, Kawasaki R, Yanagi Y. Early stages of age-related macular degeneration: racial\/ethnic differences and proposal of a new classification incorporating emerging concept of choroidal pathology. J Clin Med. 2022, 11:10.3390\/jcm11216274","journal-title":"J Clin Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.09.015","article-title":"Subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial","volume":"126","author":"Guymer RH","year":"2019","unstructured":"Guymer RH, Wu Z, Hodgson LA, et al.. Subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial. Ophthalmology. 2019, 126:829-38. 10.1016\/j.ophtha.2018.09.015","journal-title":"Ophthalmology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris FL 3rd","year":"2013","unstructured":"Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR. Clinical classification of age-related macular degeneration. Ophthalmology. 2013, 120:844-51. 10.1016\/j.ophtha.2012.10.036","journal-title":"Ophthalmology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.30","article-title":"Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington Eye Assessment Project: a cross-sectional study","volume":"31","author":"Wilde C","year":"2017","unstructured":"Wilde C, Poostchi A, Mehta RL, MacNab HK, Hillman JG, Vernon SA, Amoaku WM. Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington Eye Assessment Project: a cross-sectional study. Eye (Lond). 2017, 31:1042-50. 10.1038\/eye.2017.30","journal-title":"Eye (Lond)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S142685","article-title":"Early and intermediate age-related macular degeneration: update and clinical review","volume":"12","author":"Garc\u00eda-Layana A","year":"2017","unstructured":"Garc\u00eda-Layana A, Cabrera-L\u00f3pez F, Garc\u00eda-Arum\u00ed J, Arias-Barquet L, Ruiz-Moreno JM. Early and intermediate age-related macular degeneration: update and clinical review. Clin Interv Aging. 2017, 12:1579-87. 10.2147\/CIA.S142685","journal-title":"Clin Interv Aging"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-01933-7","article-title":"Is preventable sight loss truly preventable? An exploration of a public health indicator for sight loss due to age-related macular degeneration in England","volume":"37","author":"Brown K","year":"2023","unstructured":"Brown K, Bunce C, Onabanjo O, Strong SA, Patel PJ. Is preventable sight loss truly preventable? An exploration of a public health indicator for sight loss due to age-related macular degeneration in England. Eye (Lond). 2023, 37:516-23. 10.1038\/s41433-022-01933-7","journal-title":"Eye (Lond)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.115","article-title":"One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration","volume":"25","author":"Arora S","year":"2011","unstructured":"Arora S, McKibbin M. One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye (Lond). 2011, 25:1034-8. 10.1038\/eye.2011.115","journal-title":"Eye (Lond)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.13.27","article-title":"Inflammasome proteins as inflammatory biomarkers of age-related macular degeneration","volume":"9","author":"Weaver C","year":"2020","unstructured":"Weaver C, Cyr B, de Rivero Vaccari JC, de Rivero Vaccari JP. Inflammasome proteins as inflammatory biomarkers of age-related macular degeneration. Transl Vis Sci Technol. 2020, 9:27. 10.1167\/tvst.9.13.27","journal-title":"Transl Vis Sci Technol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01683-8","article-title":"An exploratory study to evaluate visual function endpoints in non-advanced age-related macular degeneration","volume":"20","author":"Narayanan D","year":"2020","unstructured":"Narayanan D, Rodriguez J, Wallstrom G, Welch D, Chapin M, Arrigg P, Abelson M. An exploratory study to evaluate visual function endpoints in non-advanced age-related macular degeneration. BMC Ophthalmol. 2020, 20:424. 10.1186\/s12886-020-01683-8","journal-title":"BMC Ophthalmol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11070-6","article-title":"Multispectral pattern recognition measures change in drusen area in age-related macular degeneration with high congruency to expert graders","volume":"12","author":"Nam J","year":"2022","unstructured":"Nam J, Ly A, Kalloniatis M, Nivison-Smith L. Multispectral pattern recognition measures change in drusen area in age-related macular degeneration with high congruency to expert graders. Sci Rep. 2022, 12:7442. 10.1038\/s41598-022-11070-6","journal-title":"Sci Rep"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.198","article-title":"Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26","volume":"127","author":"Lindblad AS","year":"2009","unstructured":"Lindblad AS, Lloyd PC, Clemons TE, Gensler GR, Ferris FL 3rd, Klein ML, Armstrong JR. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009, 127:1168-74. 10.1001\/archophthalmol.2009.198","journal-title":"Arch Ophthalmol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.10.047","article-title":"Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS Report No. 19","volume":"112","author":"Clemons TE","year":"2005","unstructured":"Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS Report No. 19. Ophthalmology. 2005, 112:533-9. 10.1016\/j.ophtha.2004.10.047","journal-title":"Ophthalmology"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2011.582533","article-title":"Imaging in neovascular age-related macular degeneration","volume":"26","author":"Gess AJ","year":"2011","unstructured":"Gess AJ, Fung AE, Rodriguez JG. Imaging in neovascular age-related macular degeneration. Semin Ophthalmol. 2011, 26:225-33. 10.3109\/08820538.2011.582533","journal-title":"Semin Ophthalmol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.104","article-title":"Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis","volume":"28","author":"Faes L","year":"2014","unstructured":"Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond). 2014, 28:788-96. 10.1038\/eye.2014.104","journal-title":"Eye (Lond)"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.6396","article-title":"Diagnostic accuracy of the Amsler grid test for detecting neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"141","author":"Bjerager J","year":"2023","unstructured":"Bjerager J, Schneider M, Potapenko I, et al.. Diagnostic accuracy of the Amsler grid test for detecting neovascular age-related macular degeneration: a systematic review and meta-analysis. JAMA Ophthalmol. 2023, 141:315-23. 10.1001\/jamaophthalmol.2022.6396","journal-title":"JAMA Ophthalmol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.06.008","article-title":"Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study","volume":"112","author":"Alster Y","year":"2005","unstructured":"Alster Y, Bressler NM, Bressler SB, et al.. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005, 112:1758-65. 10.1016\/j.ophtha.2005.06.008","journal-title":"Ophthalmology"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7517","article-title":"Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab","volume":"52","author":"Querques G","year":"2011","unstructured":"Querques G, Querques L, Rafaeli O, Canoui-Poitrine F, Bandello F, Souied EH. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2011, 52:7012-8. 10.1167\/iovs.11-7517","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900071","article-title":"Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy","volume":"2","author":"Fujimoto JG","year":"2000","unstructured":"Fujimoto JG, Pitris C, Boppart SA, Brezinski ME. Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. Neoplasia. 2000, 2:9-25. 10.1038\/sj.neo.7900071","journal-title":"Neoplasia"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002775","article-title":"Optical coherence tomography angiography can categorize different subgroups of choroidal neovascularization secondary to age-related macular degeneration","volume":"40","author":"Arrigo A","year":"2020","unstructured":"Arrigo A, Romano F, Aragona E, Di Nunzio C, Battista M, Bandello F, Battaglia Parodi M. Optical coherence tomography angiography can categorize different subgroups of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2020, 40:2263-9. 10.1097\/IAE.0000000000002775","journal-title":"Retina"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.227","article-title":"A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration","volume":"31","author":"Schmidt-Erfurth U","year":"2017","unstructured":"Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunovi\u0107 H. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond). 2017, 31:26-44. 10.1038\/eye.2016.227","journal-title":"Eye (Lond)"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1177\/1179172116686075","article-title":"Optical coherence tomographic angiography imaging in age-related macular degeneration","volume":"9","author":"Ma J","year":"2017","unstructured":"Ma J, Desai R, Nesper P, Gill M, Fawzi A, Skondra D. Optical coherence tomographic angiography imaging in age-related macular degeneration. Ophthalmol Eye Dis. 2017, 9:1179172116686075. 10.1177\/1179172116686075","journal-title":"Ophthalmol Eye Dis"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.887104","article-title":"Challenges in age-related macular degeneration: from risk factors to novel diagnostics and prevention strategies","volume":"9","author":"Lombardo M","year":"2022","unstructured":"Lombardo M, Serrao S, Lombardo G. Challenges in age-related macular degeneration: from risk factors to novel diagnostics and prevention strategies. Front Med (Lausanne). 2022, 9:887104. 10.3389\/fmed.2022.887104","journal-title":"Front Med (Lausanne)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2013.784792","article-title":"Adaptive optics retinal imaging--clinical opportunities and challenges","volume":"38","author":"Carroll J","year":"2013","unstructured":"Carroll J, Kay DB, Scoles D, Dubra A, Lombardo M. Adaptive optics retinal imaging--clinical opportunities and challenges. Curr Eye Res. 2013, 38:709-21. 10.3109\/02713683.2013.784792","journal-title":"Curr Eye Res"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3928\/15428877-20101031-07","article-title":"Assessing the photoreceptor mosaic over drusen using adaptive optics and SD-OCT","volume":"41","author":"Godara P","year":"2010","unstructured":"Godara P, Siebe C, Rha J, Michaelides M, Carroll J. Assessing the photoreceptor mosaic over drusen using adaptive optics and SD-OCT. Ophthalmic Surg Lasers Imaging. 2010, 41:S104-8. 10.3928\/15428877-20101031-07","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/jbio.201700095","article-title":"Assessment of trans-scleral iontophoresis delivery of lutein to the human retina","volume":"11","author":"Lombardo M","year":"2018","unstructured":"Lombardo M, Villari V, Micali N, Roy P, Sousa SH, Lombardo G. Assessment of trans-scleral iontophoresis delivery of lutein to the human retina. J Biophotonics. 2018, 11:10.1002\/jbio.201700095","journal-title":"J Biophotonics"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3390\/nu5051823","article-title":"The role of lutein in eye-related disease","volume":"5","author":"Koushan K","year":"2013","unstructured":"Koushan K, Rusovici R, Li W, Ferguson LR, Chalam KV. The role of lutein in eye-related disease. Nutrients. 2013, 5:1823-39. 10.3390\/nu5051823","journal-title":"Nutrients"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2010.05.015","article-title":"Location of macular xanthophylls in the most vulnerable regions of photoreceptor outer-segment membranes","volume":"504","author":"Subczynski WK","year":"2010","unstructured":"Subczynski WK, Wisniewska A, Widomska J. Location of macular xanthophylls in the most vulnerable regions of photoreceptor outer-segment membranes. Arch Biochem Biophys. 2010, 504:61-6. 10.1016\/j.abb.2010.05.015","journal-title":"Arch Biochem Biophys"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial","volume":"309","year":"2013","unstructured":"Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration. the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013, 309:2005-15. 10.1001\/jama.2013.4997","journal-title":"JAMA"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520180037032","article-title":"Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye disease case-control study group","volume":"9","author":"Seddon JM","year":"1994","unstructured":"Seddon JM, Ajani UA, Sperduto RD, et al.. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye disease case-control study group. JAMA. 1994, 9:1413-20. 10.1001\/jama.1994.03520180037032","journal-title":"JAMA"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-1004-y","article-title":"Association between sunlight exposure and risk of age-related macular degeneration: a meta-analysis","volume":"18","author":"Zhou H","year":"2018","unstructured":"Zhou H, Zhang H, Yu A, Xie J. Association between sunlight exposure and risk of age-related macular degeneration: a meta-analysis. BMC Ophthalmol. 2018, 18:331. 10.1186\/s12886-018-1004-y","journal-title":"BMC Ophthalmol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.22608\/APO.2017416","article-title":"Prevention of age-related macular degeneration","volume":"6","author":"Singh N","year":"2017","unstructured":"Singh N, Srinivasan S, Muralidharan V, Roy R, V J, Raman R. Prevention of age-related macular degeneration. Asia Pac J Ophthalmol (Phila). 2017, 6:520-6. 10.22608\/APO.2017416","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153297","article-title":"Prevention of the onset of age-related macular degeneration","volume":"10","author":"Di Carlo E","year":"2021","unstructured":"Di Carlo E, Augustin AJ. Prevention of the onset of age-related macular degeneration. J Clin Med. 2021, 10:10.3390\/jcm10153297","journal-title":"J Clin Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.1000","article-title":"Evaluation of a portable artificial vision device among patients with low vision","volume":"134","author":"Moisseiev E","year":"2016","unstructured":"Moisseiev E, Mannis MJ. Evaluation of a portable artificial vision device among patients with low vision. JAMA Ophthalmol. 2016, 134:748-52. 10.1001\/jamaophthalmol.2016.1000","journal-title":"JAMA Ophthalmol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn JS","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008, 27:331-71. 10.1016\/j.preteyeres.2008.05.001","journal-title":"Prog Retin Eye Res"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.125.10.1357","article-title":"Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration","volume":"125","author":"Bashshur ZF","year":"2007","unstructured":"Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2007, 125:1357-61. 10.1001\/archopht.125.10.1357","journal-title":"Arch Ophthalmol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.990379","article-title":"Current choice of treatments for neovascular AMD","volume":"8","author":"Lai K","year":"2015","unstructured":"Lai K, Landa G. Current choice of treatments for neovascular AMD. Expert Rev Clin Pharmacol. 2015, 8:135-40. 10.1586\/17512433.2015.990379","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldn012","article-title":"Age-related macular degeneration: diagnosis and management","volume":"85","author":"Cook HL","year":"2008","unstructured":"Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull. 2008, 85:127-49. 10.1093\/bmb\/ldn012","journal-title":"Br Med Bull"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice Pattern\u00ae","volume":"127","author":"Flaxel CJ","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Age-related macular degeneration preferred practice Pattern\u00ae. Ophthalmology. 2020, 127:P1-65. 10.1016\/j.ophtha.2019.09.024","journal-title":"Ophthalmology"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.2174\/1871523016666170502115816","article-title":"Designed ankyrin repeat proteins: a look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders","volume":"16","author":"Smithwick E","year":"2017","unstructured":"Smithwick E, Stewart MW. Designed ankyrin repeat proteins: a look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders. Antiinflamm Antiallergy Agents Med Chem. 2017, 16:33-45. 10.2174\/1871523016666170502115816","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.05.037","article-title":"Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study","volume":"158","author":"Souied EH","year":"2014","unstructured":"Souied EH, Devin F, Mauget-Fa\u00ffsse M, et al.. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study. Am J Ophthalmol. 2014, 158:724-32.e2. 10.1016\/j.ajo.2014.05.037","journal-title":"Am J Ophthalmol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25307","article-title":"Functional characterization of abicipar-pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability","volume":"59","author":"Rodrigues GA","year":"2018","unstructured":"Rodrigues GA, Mason M, Christie LA, et al.. Functional characterization of abicipar-pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability. Invest Ophthalmol Vis Sci. 2018, 59:5836-46. 10.1167\/iovs.18-25307","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.035","article-title":"Efficacy and safety of Abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study","volume":"127","author":"Kunimoto D","year":"2020","unstructured":"Kunimoto D, Yoon YH, Wykoff CC, et al.. Efficacy and safety of Abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020, 127:1331-44. 10.1016\/j.ophtha.2020.03.035","journal-title":"Ophthalmology"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0062","article-title":"Double-masked, randomized, Phase 2 evaluation of Abicipar pegol (an anti-VEGF DARPin therapeutic) in neovascular age-related macular degeneration","volume":"34","author":"Callanan D","year":"2018","unstructured":"Callanan D, Kunimoto D, Maturi RK, et al.. Double-masked, randomized, Phase 2 evaluation of Abicipar pegol (an anti-VEGF DARPin therapeutic) in neovascular age-related macular degeneration. J Ocul Pharmacol Ther. 2018, 34:700-9. 10.1089\/jop.2018.0062","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1159\/000517520","article-title":"Age-related macular degeneration: pathophysiology, management, and future perspectives","volume":"244","author":"Flores R","year":"2021","unstructured":"Flores R, Carneiro \u00c2, Vieira M, Tenreiro S, Seabra MC. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica. 2021, 244:495-511. 10.1159\/000517520","journal-title":"Ophthalmologica"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1636031","article-title":"Innovative therapies for neovascular age-related macular degeneration","volume":"20","author":"Al-Khersan H","year":"2019","unstructured":"Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019, 20:1879-91. 10.1080\/14656566.2019.1636031","journal-title":"Expert Opin Pharmacother"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"12","author":"Rakoczy EP","year":"2015","unstructured":"Rakoczy EP, Lai CM, Magno AL, et al.. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015, 12:2395-403. 10.1016\/S0140-6736(15)00345-1","journal-title":"Lancet"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal raav.sflt-1 for wet age-related macular degeneration","volume":"14","author":"Constable IJ","year":"2016","unstructured":"Constable IJ, Pierce CM, Lai CM, et al.. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal raav.sflt-1 for wet age-related macular degeneration. EBioMedicine. 2016, 14:168-75. 10.1016\/j.ebiom.2016.11.016","journal-title":"EBioMedicine"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.03.006","article-title":"Three-year follow-up of Phase 1 and 2A rAAV.sFLT-1 subretinal gene therapy trials for exudative age-related macular degeneration","volume":"204","author":"Rakoczy EP","year":"2019","unstructured":"Rakoczy EP, Magno AL, Lai CM, Pierce CM, Degli-Esposti MA, Blumenkranz MS, Constable IJ. Three-year follow-up of Phase 1 and 2A rAAV.sFLT-1 subretinal gene therapy trials for exudative age-related macular degeneration. Am J Ophthalmol. 2019, 204:113-23. 10.1016\/j.ajo.2019.03.006","journal-title":"Am J Ophthalmol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1159\/000337347","article-title":"Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration","volume":"228","author":"Ladas ID","year":"2012","unstructured":"Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, Rouvas AA. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration. Ophthalmologica. 2012, 228:93-101. 10.1159\/000337347","journal-title":"Ophthalmologica"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.041","article-title":"The heroes of CRISPR","volume":"164","author":"Lander ES","year":"2016","unstructured":"Lander ES. The heroes of CRISPR. Cell. 2016, 164:18-28. 10.1016\/j.cell.2015.12.041","journal-title":"Cell"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.01.006","article-title":"Factors impacting efficacy of AAV-mediated CRISPR-based genome editing for treatment of choroidal neovascularization","volume":"17","author":"Chung SH","year":"2020","unstructured":"Chung SH, Mollhoff IN, Nguyen U, et al.. Factors impacting efficacy of AAV-mediated CRISPR-based genome editing for treatment of choroidal neovascularization. Mol Ther Methods Clin Dev. 2020, 17:409-17. 10.1016\/j.omtm.2020.01.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002789","article-title":"Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) Generation 1 in patients with geographic atrophy secondary to age-related macular degeneration","volume":"41","author":"Kuppermann BD","year":"2021","unstructured":"Kuppermann BD, Patel SS, Boyer DS, et al.. Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) Generation 1 in patients with geographic atrophy secondary to age-related macular degeneration. Retina. 2021, 41:144-55. 10.1097\/IAE.0000000000002789","journal-title":"Retina"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S367089","article-title":"Emerging treatment options for geographic atrophy (GA) secondary to age-related macular degeneration","volume":"17","author":"Khan H","year":"2023","unstructured":"Khan H, Aziz AA, Sulahria H, et al.. Emerging treatment options for geographic atrophy (GA) secondary to age-related macular degeneration. Clin Ophthalmol. 2023, 17:321-7. 10.2147\/OPTH.S367089","journal-title":"Clin Ophthalmol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.03.001","article-title":"Randomized Phase IIb study of brimonidine drug delivery system generation 2 for geographic atrophy in age-related macular degeneration","author":"Freeman WR","year":"2023","unstructured":"Freeman WR, Bandello F, Souied E, et al.. Randomized Phase IIb study of brimonidine drug delivery system generation 2 for geographic atrophy in age-related macular degeneration. Ophthalmol Retina. 2023, 10.1016\/j.oret.2023.03.001","journal-title":"Ophthalmol Retina"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25030663","article-title":"A novel Eye drop candidate for age-related macular degeneration treatment: studies on its pharmacokinetics and distribution in rats and rabbits","volume":"25","author":"Choi EJ","year":"2020","unstructured":"Choi EJ, Choi GW, Kim JH, et al.. A novel Eye drop candidate for age-related macular degeneration treatment: studies on its pharmacokinetics and distribution in rats and rabbits. Molecules. 2020, 25:10.3390\/molecules25030663","journal-title":"Molecules"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.2174\/1872211308666140130093301","article-title":"Drug delivery to the back of the eye following topical administration: an update on research and patenting activity","volume":"8","author":"Boddu SH","year":"2014","unstructured":"Boddu SH, Gupta H, Patel S. Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. Recent Pat Drug Deliv Formul. 2014, 8:27-36. 10.2174\/1872211308666140130093301","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0061-z","article-title":"Cellular regeneration strategies for macular degeneration: past, present and future","volume":"32","author":"Chichagova V","year":"2018","unstructured":"Chichagova V, Hallam D, Collin J, et al.. Cellular regeneration strategies for macular degeneration: past, present and future. Eye (Lond). 2018, 32:946-71. 10.1038\/s41433-018-0061-z","journal-title":"Eye (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159274-age-related-macular-degeneration-an-exponentially-emerging-imminent-threat-of-visual-impairment-and-irreversible-blindness","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:02:38Z","timestamp":1707490958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159274-age-related-macular-degeneration-an-exponentially-emerging-imminent-threat-of-visual-impairment-and-irreversible-blindness"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":106,"URL":"https:\/\/doi.org\/10.7759\/cureus.39624","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,29]]}}}